ReviewClinical and experimental immunology2014
Multiple sclerosis treatment and infectious issues: update 2013.
Review in Clinical and experimental immunology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 43 citations in OpenAlex.
- Nasal Mucociliary Clearance and Its Relationship With Disease Severity in Patients With Multiple Sclerosis.Medical science monitor : international medical journal of experimental and clinical research · 2026Article
- A narrative review on the safety of glatiramer acetate in multiple sclerosis: focus on Europe.Therapeutic advances in chronic disease · 2025Review
- Association of multiple sclerosis with mortality in sepsis: a population-level analysis.Journal of intensive care · 2022Article
- Review
- Multiple sclerosis and COVID-19: The Swedish experience.Acta neurologica Scandinavica · 2021Review
- Assessment of ability of human adipose derived stem cells for long term overexpression of IL-11 and IL-13 as therapeutic cytokines.Cytotechnology · 2020Article
- Multiple Sclerosis Disease-Modifying Therapy and the COVID-19 Pandemic: Implications on the Risk of Infection and Future Vaccination.CNS drugs · 2020Review
- Managing Disease-Modifying Therapies and Breakthrough Activity in Multiple Sclerosis Patients During the COVID-19 Pandemic: Toward an Optimized Approach.Therapeutics and clinical risk management · 2020Review
- A case of Disseminated Herpes Zoster in a patient with Multiple Sclerosis on Glatiramer acetate.IDCases · 2020Article
- Lymphopenia and DMTs for relapsing forms of MS: Considerations for the treating neurologist.Neurology. Clinical practice · 2019Review
- Factors Associated with Patient Preferences for Disease-Modifying Therapies in Multiple Sclerosis.Journal of managed care & specialty pharmacy · 2017Article
- Peptide-Conjugated Nanoparticles Reduce Positive Co-stimulatory Expression and T Cell Activity to Induce Tolerance.Molecular therapy : the journal of the American Society of Gene Therapy · 2017Article
- [Infection risks in multiple sclerosis therapy by infusion of disease modifying drugs].Der Nervenarzt · 2015Article
- [Immunotherapy and infectious issues in multiple sclerosis. Self-injectable and oral drugs for immunotherapy].Der Nervenarzt · 2015Article
- Infection risk in patients on multiple sclerosis therapeutics.CNS drugs · 2015Review
- Oligodendrocytes engineered with migratory proteins as effective graft source for cell transplantation in multiple sclerosis.Cell medicine · 2014Article
- Neuroinflammation of the central and peripheral nervous system: an update.Clinical and experimental immunology · 2014Article
- Requirement for safety monitoring for approved multiple sclerosis therapies: an overview.Clinical and experimental immunology · 2014Review
- Disease-modifying therapy in multiple sclerosis and chronic inflammatory demyelinating polyradiculoneuropathy: common and divergent current and future strategies.Clinical and experimental immunology · 2014Review
- Monoclonal antibodies in treatment of multiple sclerosis.Clinical and experimental immunology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunomodulation and immunosuppression are generally linked to an increased risk of infection. In the growing field of new and potent drugs for multiple sclerosis (MS), we review the current data concerning infections and prevention of infectious diseases. This is of importance for recently licensed and future MS treatment options, but also for long-term established therapies for MS. Some of the disease-modifying therapies (DMT) go along with threats of specific severe infections or complications, which require a more intensive long-term monitoring and multi-disciplinary surveillance. We update the existing warning notices and infectious issues which have to be considered using drugs for multiple sclerosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.